Blueprint Medicines logo

BPMC - Blueprint Medicines Share Price

$102.9 1.5  1.5%

Last Trade - 25/01/21

Sector
Healthcare
Size
Large Cap
Market Cap £4.13bn
Enterprise Value £3.57bn
Revenue £592.8m
Position in Universe 1260th / 6623
Bullish
Bearish
Unlock BPMC Revenue
Momentum
Relative Strength (%)
1m -21.7%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -19.3%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 11.4 27.8 21.4 44.5 66.5 787.5 152
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2020,Blueprint Medicines Corp revenues increased from $15M to$759.6M. Net income totaled $399.6M vs. loss of $281.4M.Revenues reflect Collaboration revenue increase from $15Mto $744.2M. Basic Earnings per Share excludingExtraordinary Items increased from -$5.95 to $7.40.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for BPMC
Graphical History

Revenue

BPMC Revenue Unlock BPMC Revenue

Net Income

BPMC Net Income Unlock BPMC Revenue

Normalised EPS

BPMC Normalised EPS Unlock BPMC Revenue

PE Ratio Range

BPMC PE Ratio Range Unlock BPMC Revenue

Dividend Yield Range

BPMC Dividend Yield Range Unlock BPMC Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BPMC EPS Forecasts Unlock BPMC Revenue
Profile Summary

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.

Directors
Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated October 14, 2008
Public Since April 30, 2015
No. of Shareholders: 16
No. of Employees: 420
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 55,730,804
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BPMC Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BPMC
Upcoming Events for BPMC
Thursday 11th February, 2021 Estimate
Q4 2020 Blueprint Medicines Corp Earnings Release
Tuesday 4th May, 2021 Estimate
Q1 2021 Blueprint Medicines Corp Earnings Release
Frequently Asked Questions for Blueprint Medicines
What is the Blueprint Medicines share price?

As of 25/01/21, shares in Blueprint Medicines are trading at $102.9, giving the company a market capitalisation of £4.13bn. This share price information is delayed by 15 minutes.

How has the Blueprint Medicines share price performed this year?

Shares in Blueprint Medicines are currently trading at $102.9 and the price has moved by 50.86% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Blueprint Medicines price has moved by 29.02% over the past year.

What are the analyst and broker recommendations for Blueprint Medicines?

Of the analysts with advisory recommendations for Blueprint Medicines, there are there are currently 6 "buy" , 5 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Blueprint Medicines is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Blueprint Medicines next release its financial results?

Blueprint Medicines is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Blueprint Medicines dividend yield?

Blueprint Medicines does not currently pay a dividend.

Does Blueprint Medicines pay a dividend?

Blueprint Medicines does not currently pay a dividend.

When does Blueprint Medicines next pay dividends?

Blueprint Medicines does not currently pay a dividend.

How do I buy Blueprint Medicines shares?

To buy shares in Blueprint Medicines you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Blueprint Medicines?

Shares in Blueprint Medicines are currently trading at $102.9, giving the company a market capitalisation of £4.13bn.

Where are Blueprint Medicines shares listed? Where are Blueprint Medicines shares listed?

Here are the trading details for Blueprint Medicines:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: BPMC
What kind of share is Blueprint Medicines?

Based on an overall assessment of its quality, value and momentum, Blueprint Medicines is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Blueprint Medicines share price forecast 2021?

Shares in Blueprint Medicines are currently priced at $102.9. At that level they are trading at 16.42% discount to the analyst consensus target price of 0.00.

Analysts covering Blueprint Medicines currently have a consensus Earnings Per Share (EPS) forecast of 5.479 for the next financial year.

How can I tell whether the Blueprint Medicines share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Blueprint Medicines. Over the past six months, the relative strength of its shares against the market has been 14.12%. At the current price of $102.9, shares in Blueprint Medicines are trading at 18.67% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Blueprint Medicines PE Ratio?

The Blueprint Medicines PE ratio based on its reported earnings over the past 12 months is 18.66. The shares are currently trading at $102.9.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Blueprint Medicines?

Blueprint Medicines's management team is headed by:

Nicholas Lydon - IND
Alexis Borisy - DRC
Daniel Lynch - CHM
Jeffrey Albers - CEO
Anthony Boral - EVP
George Demetri - IND
Mark Goldberg - IND
Michael Landsittel - CFO
Kathryn Haviland - COO
Lonnel Coats - IND
Tracey McCain - CCO
Marion Dorsch - CSO
Christopher Murray - SVP
Debra Durso-Bumpus - CHO
Fouad Namouni - PRE
Who are the major shareholders of Blueprint Medicines?

Here are the top five shareholders of Blueprint Medicines based on the size of their shareholding:

The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 8.6% (4.79m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 6.97% (3.88m shares)
T. Rowe Price Associates, Inc. Investment Advisor
Percentage owned: 6.4% (3.57m shares)
Cadian Capital Management LP Hedge Fund
Percentage owned: 4.82% (2.69m shares)
Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 4.15% (2.31m shares)
Similar to BPMC
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.